Latigo Biotherapeutics (NASDAQ:LTGO) Issues Quarterly Earnings Results

Latigo Biotherapeutics (NASDAQ:LTGO) announced its earnings results on Thursday. The company reported ($27.59) earnings per share (EPS) for the quarter, Zacks reports.

Latigo Biotherapeutics Price Performance

Shares of LTGO opened at $23.04 on Friday. Latigo Biotherapeutics has a 52-week low of $17.22 and a 52-week high of $25.93.

Analysts Set New Price Targets

Several research firms have recently weighed in on LTGO. Wall Street Zen downgraded shares of Latigo Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Jefferies Financial Group started coverage on shares of Latigo Biotherapeutics in a research note on Tuesday. They set a “buy” rating and a $50.00 price objective for the company. Guggenheim began coverage on shares of Latigo Biotherapeutics in a report on Tuesday. They issued a “buy” rating and a $50.00 price objective for the company. Leerink Partners initiated coverage on shares of Latigo Biotherapeutics in a research note on Tuesday. They issued an “outperform” rating and a $36.00 target price on the stock. Finally, The Goldman Sachs Group assumed coverage on Latigo Biotherapeutics in a report on Tuesday. They set a “buy” rating and a $73.00 target price on the stock. Four investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $52.25.

Insider Transactions at Latigo Biotherapeutics

In other news, Director James B. Tananbaum bought 140,000 shares of Latigo Biotherapeutics stock in a transaction on Monday, August 10th. The shares were bought at an average cost of $18.00 per share, with a total value of $2,520,000.00. Following the completion of the purchase, the director directly owned 2,008,024 shares of the company’s stock, valued at approximately $36,144,432. This trade represents a 7.49% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Foresite Capital Management V, bought 140,000 shares of Latigo Biotherapeutics stock in a transaction on Monday, August 10th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $2,520,000.00. Following the completion of the purchase, the insider directly owned 2,008,024 shares of the company’s stock, valued at $36,144,432. This trade represents a 7.49% increase in their ownership of the stock. The SEC filing for this purchase provides additional information.

About Latigo Biotherapeutics

Latigo Biotherapeutics Inc is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Its lead product candidate includes LTG-001. Latigo Biotherapeutics Inc is based in THOUSAND OAKS, Calif.